Kallelse till extra bolagsstämma i ODI Pharma AB (publ)
News
We're thrilled to share the latest developments from our company.
Notice of Extraordinary General Meeting in ODI Pharma AB (publ)
Proposal for change in the Board of Directors of ODI Pharma AB
ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report
Publication of year-end report for the fiscal year 2023/2024
ODI Pharma AB announces strategic market entry with initial shipment to Switzerland
ODI Pharma AB: Publication of interim report Q3 2023/2024
Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024
ODI Pharma AB: Updated market and business overview
ODI Pharma AB: Publication of half-year report 2023/2024
ODI Pharma AB anlitar Pareto Securities AB som likviditetsgarant
ODI Pharma AB appoints Pareto Securities AB as liquidity provider
Announcement from the Annual General Meeting in ODI Pharma AB (publ)
Kommuniké från årsstämma i ODI Pharma AB (publ)
ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
Rättelse: ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023
ODI Pharma AB: Publication of interim report report Q1 2023/2024
ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023